Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 95Terminated 23Unknown 10Withdrawn 3Active not recruiting 3Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 3CNS 3Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Pancreatic Neoplasms 2Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Fluorouracil 51Oxaliplatin 49Gemcitabine 47Leucovorin 41Capecitabine 35Bevacizumab 29Irinotecan 25Cisplatin 22Radiotherapy 18Radiosurgery 18pembrolizumab 16Nivolumab 16Cetuximab 15Taxes 14Sorafenib 14Paclitaxel 13Biopsy 13Surgical Procedures, Operative 12Drug Therapy 11atezolizumab 10Radiation 10Albumin-Bound Paclitaxel 10lenvatinib 9durvalumab 9Magnetic Resonance Spectroscopy 9Folfox protocol 9Cyclophosphamide 9130-nm albumin-bound paclitaxel 9spartalizumab 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT00728000 2019-11-25

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

University of Cincinnati

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01600807 2013-06-26

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Dana-Farber Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT00293436 2012-09-17

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

University of California, San Francisco

Phase 1/2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡